Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Henry Fernandez
AddedMar 31, 2024
UpdatedMay 31, 2026
Henry Fernandez

Henry Fernandez

Chairman and CEO, MSCI

CrunchbaseLinkedIn

Henry Fernandez's Career

MSCI
MSCI

New York City, NY, US

Chairman and CEO· C-Suite · Board Member
Stanford Graduate School of Business
Stanford Graduate School of Business

Stanford, CA, US

Board Member· Board
Royalty Pharma
Royalty Pharma

New York City, NY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Henry Fernandez's Career

MSCI
MSCI
Public4.8k1969New York City, NY, US
Chairman and CEO· C-Suite · Board Member

Recent news

MSCI Reports Financial Results for First Quarter 2026Business Wire · 2026
MSCI Reports Financial Results for Fourth Quarter and Full Year 2025Business Wire · 2026
MSCI Reports Financial Results for Third Quarter and Nine Months 2025Business Wire · 2025

Leadership at MSCI

Marcus L. SmithMarcus L. SmithBoard Member
Robert AsheRobert AsheBoard Member
Catherine R KinneyCatherine R KinneyBoard Member
Linda RieflerLinda RieflerBoard Member
C D Baer PettitC D Baer PettitAdvisor

Similar to MSCI

MorningstarMorningstarChicago, IL, USEvents, Investment Researchest. 1984MorningstarChicago, IL, US · est. 1984

Morningstar provides independent investment research, data, and analytics to individual investors, financial advisors, and institutional clients worldwide.

Public · $91M11.1k
Capital IQCapital IQNew York City, NY, USest. 2010Capital IQNew York City, NY, US · est. 2010

NYC-based software company, S&P Capital IQ, offers efficient financial intelligence and analysis tools.

Acquired Subsidiary · $8M3k
S&P GlobalS&P GlobalNew York City, NY, USest. 1888S&P GlobalNew York City, NY, US · est. 1888

S&P Global is a publicly traded financial information and analytics company headquartered in New York City.

Public · $750M
FactSet Research SystemsFactSet Research SystemsNorwalk, CT, USest. 1978FactSet Research SystemsNorwalk, CT, US · est. 1978

Financial data and analytics company serving investment professionals worldwide.

Public12.8k
Stanford Graduate School of Business
Stanford Graduate School of Business
3.7k1925Stanford, CA, US
Board Member· Board

Leadership at Stanford Graduate School of Business

Herbert HooverHerbert HooverCo-Founder
Vineet SingalVineet SingalCo-Founder
Ankur SharmaAnkur SharmaBoard Member
Sarah SteinSarah SteinBoard Member
Jim NeesenJim NeesenCEO
Jeff EpsteinJeff EpsteinBoard Member

Similar to Stanford Graduate School of Business

Stanford UniversityStanford UniversityStanford, CA, USEducation, Researchest. 1891Stanford UniversityStanford, CA, US · est. 1891

Stanford University: A prestigious private research institution in California, educating over 17,000 students.

Series B · $20.9M16.7k
Harvard Business SchoolHarvard Business SchoolBoston, MA, USBusiness Educationest. 1908Harvard Business SchoolBoston, MA, US · est. 1908

Harvard Business School: A premier Boston-based institution offering graduate business education and publishing resources.

17.6k
Columbia Business SchoolColumbia Business SchoolNew York City, NY, USMBAest. 1916Columbia Business SchoolNew York City, NY, US · est. 1916

Columbia Business School: A prestigious Ivy League institution, shaping global business since 1916.

2.5k
Stanford Law SchoolStanford Law SchoolStanford, CA, USLegal Educationest. 1893Stanford Law SchoolStanford, CA, US · est. 1893

Stanford Law School, a prestigious branch of Stanford University, excels in legal education since 1893.

1k
Royalty Pharma
Royalty Pharma
Public751996New York City, NY, US
Board Member· Board

Leadership at Royalty Pharma

Rory RiggsRory RiggsBoard Member
Cathy EngelbertCathy EngelbertBoard Member
Pablo G LegorretaPablo G LegorretaBoard Member
David HodgsonDavid HodgsonBoard Member
Ted LoveTed LoveBoard Member
Christopher HiteChristopher HiteBoard Member

Similar to Royalty Pharma

Roivant SciencesRoivant SciencesNew York City, NY, USDrug Developmentest. 2014Roivant SciencesNew York City, NY, US · est. 2014

NY-based Roivant Sciences is a biopharmaceutical firm dedicated to advancing promising drugs for patient care.

Public · $2.5B267
XOMA RoyaltyXOMA RoyaltyEmeryville, CA, USRoyalty Acquisitionest. 1981XOMA RoyaltyEmeryville, CA, US · est. 1981

XOMA Corporation, a biotech royalty aggregator, acquires economic rights to clinical candidates, aiding health improvement.

Public · $295.8M96
AstraZenecaAstraZenecaCambridge, Cambridgeshire, GBPharmaceuticalsest. 1999AstraZenecaCambridge, Cambridgeshire, GB · est. 1999

AstraZeneca PLC: A British-Swedish firm specializing in research, manufacturing, and sales of pharmaceuticals.

Public · $3.8B83.5k
PharmosPharmosIselin, NJ, USDrug Developmentest. 1982PharmosIselin, NJ, US · est. 1982

W World Corp.: A bio-pharmaceutical firm innovating new drugs for neuroinflammatory disorders.

Public · $9.5M2

Henry Fernandez's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Henry Fernandez

Robin MatlockRobin MatlockBoard Member · People.aiPaul RoyPaul RoyBoard Member · Bloc VenturesHung Yie-HsinHung Yie-HsinBoard Member · Madison Capital FundingScott PowersScott PowersBoard Member · Sun Life FinancialTom MeredithTom MeredithBoard Member · IPX